IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas
- 240 Downloads
Most primary central nervous system lymphomas (PCNSLs) and primary vitreoretinal lymphomas (PVRLs) are B-cell lymphomas that produce high levels of interleukin (IL)-10, which is linked to rapid disease progression. The IL-10 -1082 G → A polymorphism (IL-10 SNP) is associated with improved survival in certain non-CNS lymphoma patients. PDCD4 is a tumor suppressor gene and upstream regulator of IL-10. This study examined the correlation between the IL-10 SNP, PDCD4 mRNA expression, and IL-10 expression (at transcript and protein levels) in these lymphoma cells.
Materials and methods
Single-nucleotide polymorphism (SNP)-typing at IL-10 -1082 was performed after microdissecting cytospun PVRL cells from 26 specimens. Vitreal IL-10 and IL-6 levels were measured by ELISA. PCNSL cells from 52 paraffin-embedded sections were microdissected and SNP typed on genomic DNA. RT-PCR was performed to analyze expression of IL-10 and PDCD4 mRNA. IL-10 -1082 SNP typing was performed on blood samples of 96 healthy controls. We measured IL-10 -1082 SNP expression in 26 PVRLs and 52 PCNSLs and examined its relationship with IL-10 protein and gene expression, respectively.
More PVRL patients expressed one copy of the IL-10 -1082 G → A SNP with the GA genotype compared to controls. The frequencies of the three genotypes (AA, AG, GG) significantly differed in PVRL versus controls and in PCNSL versus controls. In PVRLs, the vitreal IL-10/IL-6 ratio was higher in IL-10 -1082 AG and IL-10 -1082 AA patients, compared to IL-10 -1082 GG patients. IL-10 mRNA expression was higher in IL-10 -1082 AG and IL-10 -1082 AA PCNSLs, compared to IL-10 -1082 GG PCNSLs. No correlation was found between IL-10 and PDCD4 expression levels in 37 PCNSL samples.
PVRL and PCNSL patients had similar IL-10 -1082 A allele frequencies, but genotype distributions differed from healthy controls. The findings suggest that the IL-10 -1082 A allele is a risk factor for higher IL-10 levels in PVRLs and PCNSLs. Higher IL-10 levels have been correlated with more aggressive disease in both PVRLs and PCNSLs, making this finding an important and potentially clinically significant observation.
KeywordsPrimary vitreoretinal lymphoma Primary CNS lymphoma Interleukin-10 Single-nucleotide polymorphism PDCD4 (program cell death 4)
We would like to thank the National Eye Institute Intramural Research Program, Howard Hughes Medical Institute, Research to Prevent Blindness’s unrestricted grant to Casey Eye Institute, the Schnitzer-Novack Foundation, and the Eye Tumour Research Fund for financial support. We thank Dr. Nussenblatt and the NEI clinical fellows for the contribution of their patients’ vitreous specimen to this study. We also appreciate the physicians from other institutions who provided vitreous specimens.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.O’Neill BP (2004) Epidemiology of primary CNS lymphoma. In: Lymphoma of the nervous system. Butterworth-Heinemann, Boston, pp 1–207Google Scholar
- 5.Banchereau J, Schmitt D (1995) Dendritic cells in fundamental and clinical immunology. In: Advances in experimental medicine and biology. Plenum Press, New York, pp 1–572, Volume 2Google Scholar
- 6.Kleihues PC, WK (2000) Pathology and genetics of tumours of the nervous system. In: World Health Organization classification of tumors. Lyon, France, pp 1–314Google Scholar
- 8.Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 16:1589–1599PubMedCrossRefGoogle Scholar
- 10.Fast stats: Statistics stratified by cancer site: National Cancer Institute. Surveillance, Epidemiology, and End Results. Accessed May 8, 2011Google Scholar
- 13.Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105:13520–13525PubMedCrossRefGoogle Scholar
- 21.Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161:2099–2105PubMedGoogle Scholar
- 22.Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101–4108PubMedCrossRefGoogle Scholar
- 24.Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28:704–712PubMedCrossRefGoogle Scholar
- 25.Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38PubMedCrossRefGoogle Scholar
- 27.Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, Montalban C, Guma J, Bosch R, Wang SS, Lan Q, Whitby D, Fernandez de Sevilla A, Rothman N, de Sanjose S (2007) Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 92:1475–1481PubMedCrossRefGoogle Scholar